Summary
AbbVie Inc. reported strong top-line growth in the second quarter and first half of 2020, driven significantly by the completion of the Allergan acquisition on May 8, 2020. This strategic acquisition has diversified AbbVie's revenue base and expanded its leadership across key therapeutic areas including immunology, oncology, aesthetics, neuroscience, eye care, and women's health. Despite the significant operational changes and integration costs associated with the Allergan acquisition, AbbVie demonstrated robust revenue growth across its portfolio, with notable contributions from its immunology and oncology franchises. The company also highlighted continued investment in its pipeline and a commitment to returning cash to shareholders through dividends. While the COVID-19 pandemic presented some headwinds, particularly in new patient starts for certain products, AbbVie has managed its supply chain effectively and continues to assess the evolving impact of the pandemic.
Financial Highlights
56 data points| Revenue | $10.43B |
| Cost of Revenue | $3.71B |
| Gross Profit | $6.71B |
| SG&A Expenses | $3.53B |
| Operating Expenses | $9.67B |
| Operating Income | $752.00M |
| Interest Expense | $632.00M |
| Net Income | -$738.00M |
| EPS (Basic) | $-0.46 |
| EPS (Diluted) | $-0.46 |
| Shares Outstanding (Basic) | 1.65B |
| Shares Outstanding (Diluted) | 1.65B |
Key Highlights
- 1Completed the transformative acquisition of Allergan plc on May 8, 2020, significantly diversifying the company's business and creating leadership positions in new therapeutic areas.
- 2Reported strong revenue growth, with total net revenues increasing by 26.3% to $10.4 billion for the three months ended June 30, 2020, and by 18.4% to $19.0 billion for the six months ended June 30, 2020.
- 3Demonstrated significant growth in key products such as Skyrizi and Rinvoq within the Immunology segment, and continued strength in Imbruvica and Venclexta within Hematologic Oncology.
- 4Experienced a net loss of $738 million ($0.46 per share) for the three months ended June 30, 2020, primarily due to substantial acquisition-related expenses, including amortization of intangible assets and changes in contingent consideration.
- 5The balance sheet reflects a substantial increase in intangible assets ($76.5 billion) and goodwill ($42.7 billion) post-Allergan acquisition, reflecting the significant value assigned to acquired assets.
- 6Operating cash flow remained strong, with $6.9 billion generated in the first six months of 2020, despite significant cash outflows for the Allergan acquisition.
- 7AbbVie continues to manage its product portfolio, with Humira sales showing resilience in the U.S. but facing biosimilar competition internationally, while products like Mavyret saw significant declines.